We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Voyager Therapeutics (VYGR) Surges 11.1%: Is This an Indication of Further Gains?
Read MoreHide Full Article
Voyager Therapeutics (VYGR - Free Report) shares rallied 11.1% in the last trading session to close at $7.71. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 10% loss over the past four weeks.
The surge in the stock price is likely to be an outcome of the positive momentum built around the company's pipeline. The company is developing early-stage programs in gene therapy and neurology. Voyager will report its first-quarter 2023 earnings on May 9, before market opens.
This gene therapy company is expected to post quarterly earnings of $1.68 per share in its upcoming report, which represents a year-over-year change of +400%. Revenues are expected to be $99.33 million, up 14950% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Voyager Therapeutics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on VYGR going forward to see if this recent jump can turn into more strength down the road.
Voyager Therapeutics is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Legend Biotech Corporation Sponsored ADR (LEGN - Free Report) , finished the last trading session 1% higher at $66.32. LEGN has returned 41.8% over the past month.
For Legend Biotech Corporation Sponsored ADR, the consensus EPS estimate for the upcoming report has changed +10.7% over the past month to -$0.56. This represents a change of -133.3% from what the company reported a year ago. Legend Biotech Corporation Sponsored ADR currently has a Zacks Rank of #3 (Hold).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Voyager Therapeutics (VYGR) Surges 11.1%: Is This an Indication of Further Gains?
Voyager Therapeutics (VYGR - Free Report) shares rallied 11.1% in the last trading session to close at $7.71. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 10% loss over the past four weeks.
The surge in the stock price is likely to be an outcome of the positive momentum built around the company's pipeline. The company is developing early-stage programs in gene therapy and neurology. Voyager will report its first-quarter 2023 earnings on May 9, before market opens.
This gene therapy company is expected to post quarterly earnings of $1.68 per share in its upcoming report, which represents a year-over-year change of +400%. Revenues are expected to be $99.33 million, up 14950% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Voyager Therapeutics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on VYGR going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Voyager Therapeutics is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Legend Biotech Corporation Sponsored ADR (LEGN - Free Report) , finished the last trading session 1% higher at $66.32. LEGN has returned 41.8% over the past month.
For Legend Biotech Corporation Sponsored ADR, the consensus EPS estimate for the upcoming report has changed +10.7% over the past month to -$0.56. This represents a change of -133.3% from what the company reported a year ago. Legend Biotech Corporation Sponsored ADR currently has a Zacks Rank of #3 (Hold).